Skip to main
SVRA
SVRA logo

Savara (SVRA) Stock Forecast & Price Target

Savara (SVRA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Savara Inc. is experiencing a positive outlook due to a recent increase in estimated peak annual sales for its molgramostim nebulizer solution, now projected at $962 million compared to prior estimates of $680 million. The company's management has provided updated pricing estimates, anticipating a list price for Molbreevi in the range of $400,000 to $500,000, leading to an increased launch price estimate of $425,000. These developments, along with a consistent stream of positive updates, have prompted analysts to revise their discounted cash flow-derived price target for Savara shares upwards to $11.

Bears say

Savara Inc. faces a challenging outlook due to potential delays in regulatory approval for its molgramostim nebulizer solution, which could severely hinder market entry and, consequently, sales and market share. The company also reported higher-than-anticipated research and development (R&D) and selling, general, and administrative (SG&A) expenses, coupled with lower total other income, which negatively affects its financial health. Furthermore, there has been a decrease in projected peak market penetration rates, indicating potential difficulties in achieving growth targets.

Savara (SVRA) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Savara (SVRA) Forecast

Analysts have given Savara (SVRA) a Buy based on their latest research and market trends.

According to 6 analysts, Savara (SVRA) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Savara (SVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.